Gilead Sciences | GILD - Assets

Stock Price
140.15
Daily Change
0.44 0.31%
Monthly
-4.42%
Yearly
32.82%
Q2 Forecast
135.50

Gilead Sciences reported $59.02B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025